Vitamins A, C, E + selenium + zinc vs placebo
The review found no eligible studies for this question.
- no estimate extractedStudies not reportedNo studies found
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Vitamins A, C, E + selenium + zinc showed no clear difference in incidence: all cancers compared with placebo (high certainty).
The review found no eligible studies for this question.
Vitamins A, C, E + selenium + zinc showed no clear difference in mortality: all causes compared with placebo (high certainty).
Vitamin A showed no clear difference in incidence: all cancers compared with placebo (high certainty).
Vitamin A showed no clear difference in mortality: all cancers compared with placebo (high certainty).
Vitamin A leads to higher mortality: all causes ‐ smokers and asbestos workers compared with placebo (high certainty).
Vitamin C showed no clear difference in incidence: lung cancer compared with placebo (moderate certainty).
Vitamin C showed no clear difference in incidence: lung cancer ‐ men compared with placebo (high certainty).
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes adverse events: diarrhoea compared with placebo (very low certainty).
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FEV1 % predicted compared with placebo (very low certainty).
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FVC % predicted compared with placebo (very low certainty).
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes growth and nutrition: BMI SD score compared with placebo (very low certainty).
Rituximab probably leads to lower relapses at 3 months compared with placebo or control (moderate certainty).
Rituximab probably leads to lower relapses at 6 months compared with placebo or control (moderate certainty).
Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).
Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).